Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01YYP
|
|||
| Former ID |
DIB009572
|
|||
| Drug Name |
Margetuximab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | HER2-positive breast cancer [ICD-11: 2C60-2C65] | Approved | [1] | |
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 2 | [2], [3] | ||
| Gastrointestinal cancer [ICD-11: 2C11] | Phase 2 | [4], [5] | ||
| Company |
Macrogenics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8686). | |||
| REF 5 | ClinicalTrials.gov (NCT01828021) Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.